Mature Results of the Ottawa Phase II Study of Intermittent Androgen-Suppression Therapy in Prostate Cancer: Clinical Predictors of Outcome

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 3, 2007, Pages 699-706

  Malone, Shawn ^a   Perry, Gad ^a   Eapen, Libni ^a   Segal, Roanne ^a   Gallant, Victor ^b   Dahrouge, Simone ^c   Crook, Juanita ^d   Spaans, Johanna N ^e  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c BRUYÈRE RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Intermittent hormone therapy; Prostate cancer; Recurrent prostate cancer

Indexed keywords

ANTIGENS; BIOCHEMISTRY; DISEASES; HORMONES; PATIENT TREATMENT; PROBABILITY;

ANDROGEN DEPRIVATION THERAPY (ADT); INTERMITTENT HORMONE THERAPY; PROSTATE CANCER; RECURRENT PROSTATE CANCER;

ONCOLOGY;

LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FATIGUE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; MUSCLE WEAKNESS; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; REGRESSION ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; VOMITING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CLINICAL TRIALS, PHASE II; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONTARIO; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34249326609     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.12.072     Document Type: Article

References (23)

1. Fusi A., Procopio G., Della Torre S., et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 90 (2004) 535-546
2. Tannock I.F., de Wit R., Berry W.R., et al. The TAX 327 Investigators (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
3. Strum S., McDermid J., Scholz M., et al. Anemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79 (1997) 933-941
4. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181-186
5. Maillefert J.F., Sibilia J., Michel F., et al. Bone mineral density in men treated with synthetic gonadotrophin-releasing agonists for prostate carcinoma. J Urol 161 (1999) 1219-1222
6. Bruchovsky N., Rennie P.S., Coldman A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
7. Akakura K., Bruchovsky N., Goldenberg L., et al. Effects of intermittent androgen suppression on androgen dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
8. Goldenberg S.L., Bruchovski N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45 (1995) 839-844
9. Bouchot O., Lenormand L., Karam G., et al. Intermittent suppression in the treatment of metastatic prostate cancer. Eur Urol 38 (2000) 543-549
10. Strum S.B., Sholz M.C., and McDermed J.E. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy. Oncologist 5 (2000) 45-52
11. Goldenberg S.L., Gleave M.E., Taylor D., et al. Clinical experience with intermittent androgen suppression in prostate cancer: Minimum of 3 years follow-up. Mol Urol 3 (1999) 287-292
12. Egawa S., Takashima R., Matsumoto K., et al. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Jpn J Clin Oncol 30 (2000) 21-26
13. Crook J.M., Szumacher E., Malone S., et al. Intermittent androgen suppression in the management of prostate cancer. Urology 53 (1999) 530-534
14. Kurek R., Renneberg H., Lubben G., et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 (1999) 27-31
15. Malone S., Donker R., Perry G., et al. Long term side effects of intermittent androgen suppression therapy (IAS) in prostate cancer: Results of a Phase II study. [Abstract]. Proc Amer Soc Clin Oncol 20 (2001) 2390
16. Higano C.S., Ellis W., Russell K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 48 (1996) 800-804
17. Malone S., Perry G., Segal R., Dahrouge S., and Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: Results of a Phase II study. Br J Urol Int 96 (2005) 514
18. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem 92 (2004) 287-295
19. Hormone therapy in treating patients with rising PSA levels following radiation therapy for prostate cancer. National Cancer Institute (NCI), Southwest Oncology Group, NCIC-Clinical Trials Group.
20. Lane T.M., Ansell W., Farrugia D., et al. Long-term outcome in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 73 (2004) 117-122
21. De La Taille A., Zerbib M., Conquy S., et al. Intermittent androgen suppression in patients with prostate cancer. Br J Urol Int 91 (2003) 18-22
22. Strum S.B., Sholz M.C., and McDermed J.E. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy. Oncologist 5 (2000) 45-52
23. Gossfeld G.D., Small E.J., and Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience. Urology 51 (1998) 137-144